Cell Therapy News

The FDA’s approval of tisagenlecleucel in 2017 resulted in an explosion of research into chimeric antigen receptor T-cell therapies.

Steven A. Rosenberg, MD, PhD, FAACR, will receive this year’s Pezcoller Foundation-American Association of Cancer Research International Award for Extraordinary Achievement in Cancer Research.

Krishna Komanduri, MD, has been appointed division chief of hematology-oncology at UCSF Health.

Commercially available chimeric antigen receptor T cells for acute myeloid leukemia could be just a few years away, according to a presenter at the inaugural Personalizing Pediatric Cancer Care Summit.

The University of Texas MD Anderson Cancer announced Thursday the launch of the James P. Allison Institute, a research and innovation hub that integrates immunobiology across disciplines to accelerate discoveries toward cancer cures.

B-cell activating factor is a ligand protein, which makes it uniquely suited as a therapeutic option for the newly emerging class of multitargeted chimeric antigen receptor T-cell therapies.

Early in my career, I received a career development award from a scientific society to further my research on cellular therapies in hematologic malignancies.

Early intrathecal therapy effectively resolved symptoms related to high-grade neurotoxicity among patients who received chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma, according to a research letter in JAMA Oncology.

J. Joseph Melenhorst, PhD, has been appointed director of Cleveland Clinic’s new cell therapy and immuno-engineering program.

The FDA granted orphan drug designation to WU-CART-007 for patients with relapsed or refractory T-cell acute lymphoblastic leukemia.